Winter M, Ebner S, Scheuber N, Schulze F, Kinzler M, Walter D
Cancers (Basel). 2025; 17(5).
PMID: 40075667
PMC: 11898960.
DOI: 10.3390/cancers17050820.
Garcia Megias I, Almeida L, Calapaqui Teran A, Pabst K, Herrmann K, Giammarile F
Ann Nucl Med. 2025; .
PMID: 40069442
DOI: 10.1007/s12149-025-02022-x.
ODonnell C, Majeed U, Rutenberg M, Croome K, Poruk K, Toskich B
Curr Oncol. 2025; 32(2).
PMID: 39996882
PMC: 11854535.
DOI: 10.3390/curroncol32020082.
Beaudry F, Li Z, Borgida A, Zorigtbaatar A, Wang X, Hildebrand M
Curr Oncol. 2025; 32(2).
PMID: 39996880
PMC: 11854319.
DOI: 10.3390/curroncol32020080.
Camera S, Rossari F, Foti S, Vitiello F, Persano M, Prinzi F
Target Oncol. 2025; .
PMID: 39985696
DOI: 10.1007/s11523-025-01132-w.
Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data.
Li Z, Aliseda D, Jones O, Rajendran L, Magyar C, Grant R
JHEP Rep. 2025; 7(3):101290.
PMID: 39980751
PMC: 11840543.
DOI: 10.1016/j.jhepr.2024.101290.
Open versus laparoscopic oncologic resection for gallbladder cancer after index cholecystectomy: international multicenter comparative study.
Masior L, Krasnodebski M, Kruk E, de Santibanes M, Uad P, Ramos J
Langenbecks Arch Surg. 2025; 410(1):74.
PMID: 39961819
PMC: 11832698.
DOI: 10.1007/s00423-025-03643-6.
Focal acute cholecystitis misdiagnosed as gallbladder carcinoma.
DAlessandro G, Ancona G, Dellafiore C, Raimondi A, Gangemi D, Arpa G
J Ultrasound. 2025; .
PMID: 39948290
DOI: 10.1007/s40477-025-00995-z.
Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866.
Taguchi D, Shirakami Y, Sakai H, Minowa D, Miwa T, Maeda T
Int J Mol Sci. 2025; 26(3).
PMID: 39940750
PMC: 11817608.
DOI: 10.3390/ijms26030978.
First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort.
Adamus N, Edeline J, Henriques J, Fares N, Lecomte T, Turpin A
JHEP Rep. 2025; 7(2):101279.
PMID: 39897613
PMC: 11786833.
DOI: 10.1016/j.jhepr.2024.101279.
Application value of F-FDG PET/CT in soft tissue metastasis of intrahepatic cholangiocarcinoma: a case report and literature review.
Liu S, Sun X, Liu Y, Shi N, Zhang X, Yu Y
Front Oncol. 2025; 14:1474105.
PMID: 39886669
PMC: 11779615.
DOI: 10.3389/fonc.2024.1474105.
Management of intrahepatic cholangiocarcinoma: a review for clinicians.
Colangelo M, Di Martino M, Polidoro M, Forti L, Tober N, Gennari A
Gastroenterol Rep (Oxf). 2025; 13:goaf005.
PMID: 39867595
PMC: 11769681.
DOI: 10.1093/gastro/goaf005.
ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer.
Vogel A, Ducreux M
ESMO Open. 2025; 10(1):104003.
PMID: 39864891
PMC: 11846563.
DOI: 10.1016/j.esmoop.2024.104003.
The Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.
Cammarota A, Balsano R, Pressiani T, Bozzarelli S, Rimassa L, Lleo A
Cancers (Basel). 2025; 17(2).
PMID: 39858054
PMC: 11763448.
DOI: 10.3390/cancers17020272.
Efficacy of microwave ablation for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Song M, Li J, Li Y, Zhang C, Sigdel M, Hou R
Quant Imaging Med Surg. 2025; 15(1):760-769.
PMID: 39839012
PMC: 11744144.
DOI: 10.21037/qims-24-607.
Prognostic factors for survival in patients with advanced cholangiocarcinoma treated with percutaneous transhepatic drainage.
Rohan T, Cechova B, Matkulcik P, Straka M, Zavadil J, Eid M
Sci Rep. 2025; 15(1):2172.
PMID: 39824949
PMC: 11742682.
DOI: 10.1038/s41598-025-86443-8.
Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma.
Tesini G, Braconi C, Rimassa L, Macias R
Cancers (Basel). 2025; 17(1.
PMID: 39796782
PMC: 11719734.
DOI: 10.3390/cancers17010156.
Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection.
Yu J, He A, Ouf M, Mehta R, Anaya D, Denbo J
JCO Precis Oncol. 2025; 9():e2400443.
PMID: 39772829
PMC: 11723488.
DOI: 10.1200/PO-24-00443.
Prognostic Significance of Lymphocyte-to-Monocyte Ratio in Patients With Unresectable Biliary Tract Cancer Undergoing Systemic Chemotherapy.
Suzuki H, Kuwano A, Takahira J, Tanaka K, Yada M, Motomura K
Cancer Diagn Progn. 2025; 5(1):132-137.
PMID: 39758246
PMC: 11696337.
DOI: 10.21873/cdp.10422.
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer.
Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M
Mol Biomed. 2025; 6(1):2.
PMID: 39757310
PMC: 11700966.
DOI: 10.1186/s43556-024-00239-2.
